Evidence is accumulating that circulating 1,25-dihydroxyvitamin D [1,25(OH) 2 D] concentrations are inversely related to overall mortality.
Vitamin D deficiency is regarded as a worldwide health problem that probably affects not only musculoskeletal health, but also a wide range of acute and chronic diseases (1 ) . Vitamin D itself is biologically inert and needs a 25-hydroxylation in the liver and a 1␣-hydroxylation in the kidney to be converted into its active, hormonal form 1,25-dihydroxyvitamin D [1, 25(OH) 2 D]. 5 The measurement of circulating concentrations of 25-hydroxyvitamin D (25OHD) is the hallmark for determining human vitamin D status. Cutoffs for different stages of vitamin D status, such as deficiency, inadequacy, adequacy, and potentially harmful values, have been defined and are based on associations between circulating 25OHD concentrations and physiological/clinical alterations in the human body (2) (3) . Mortality, as the most important adverse outcome, is significantly increased in individuals with deficient and insufficient circulating 25OHD concentrations, e.g., values below 50 nmol/L (4 ).
So far, circulating 1,25(OH) 2 D concentrations have received relatively little attention, except in chronic kidney disease (CKD) patients. The reference range for circulating 1,25(OH) 2 D is not well defined. By statistical approaches that assume a gaussian distribution of apparently healthy individuals, the reference interval for healthy adults is 38 -134 pmol/L (divide by 2.4 to con-vert pmol/L to pg/mL) (5 ) . Usually, the 1,25(OH) 2 D concentration is homeostatically regulated. However, in addition to poor kidney function, diabetes mellitus, high concentrations of the inflammatory marker C-reactive protein, and high EuroScore values (a cardio-surgical risk marker) are also independently associated with low circulating 1,25(OH) 2 D concentrations (6 ) . Some clinical studies indicate that circulating 1,25(OH) 2 D is a better predictor of short-term or midterm mortality than circulating 25OHD (7) (8) (9) . Thus, the clinical relevance of circulating 1,25(OH) 2 D is probably underappreciated.
A recent Cochrane review of randomized controlled trials (RCTs) (10 ) supports the assumption of beneficial vitamin D effects on survival; in adult vitamin D 3 users (including individuals with and without calcium cosupplementation) mortality risk is reduced by 6%, and by 7% if only RCTs with a low risk of bias are considered. Another recent metaanalysis has demonstrated that in patients receiving vitamin D 3 alone, mortality risk is reduced by 11% (11 ) 
Methods
We planned, conducted, and reported this systematic review and metaanalysis on the basis of a protocol that was developed in accordance with the PRISMA statement (14 ) . The metaanalysis was registered at the PROSPERO international prospective register of systematic reviews as CRD42015017326.
ELIGIBILITY CRITERIA
Eligible for inclusion were randomized controlled trials with a control group receiving a placebo instead of vitamin D/activated vitamin D. Measurement of change in circulating 1,25(OH) 2 D was a necessary condition for study eligibility and this change had to be reported for each study cohort separately. We excluded studies in which only one bolus dose of vitamin D/activated vitamin D was administered, vitamin D/activated vitamin D was not administered orally, or studies were performed in infants or pregnant/lactating women. We applied no language or time restrictions, and there were no limitations with regard to patient characteristics and vitamin D dose. . We searched for the keywords in the headers and in the abstract, when available. Titles and abstracts of records identified in the primary search were screened, and all articles deemed potentially eligible for inclusion were retrieved in full-text format. We also manually searched references that were cited in the selected articles and in published reviews. The search was performed independently by 2 researchers (A. Zittermann and J.B. Ernst). Group discussion resolved any disagreement about article selection.
DATA EXTRACTION
We selected a list of demographic characteristics before conducting the data searches. This list was constructed as a series of records and included information about the study participants' characteristics and dose-response relationships. In brief, we recorded study characteristics such as date of publication, country of origin, and the number of study participants. We also extracted data about the study participants that included age, sex, ethnicity, and diseases. We documented dose, frequency, duration, and type of vitamin D supplement (D 2 or D 3 ) or activated vitamin D form (1␣-vitamin D 3 , calcitriol, or paricalcitol). In cases in which vitamin D was not administered daily, we calculated the daily dose by dividing the administered dose by its frequency (i.e., 350 g weekly represented a daily dose of 50 g). In several trials, the vitamin D intervention was combined with a calcium supplement and we abstracted this information. Finally, we recorded the method of 1,25(OH) 2 (16 ) . The potential impact of various patient and trial-level parameters on the trial outcome was investigated by means of prespecified, random-effects metaregressions. To investigate whether publication bias might affect the validity of the estimates, we constructed funnel plots of the regression of observed effect sizes against the corresponding SEs, weighted by the inverse of the pooled variance (17 ) . Publication bias was first detected by visual inspection and then with the parametric Egger test and the nonparametric Begg-Mazumdar test. Study quality was assessed according to a tool provided by the Cochrane Handbook for Systematic Reviews of Interventions (18 ) . In sensitivity analysis, we evaluated changes in circulating 1,25(OH) 2 D in studies with a low risk of bias only. Studies were deemed to have a low risk of bias if (a) the investigators described a random component in the sequence generation process, (b) participants and investigators enrolling participants could not foresee assignment, (c) blinding of participants and key study personnel was ensured, (d) blinding of outcome assessment was ensured and complete data were reported, (e) the published reports included all expected outcomes, and (f) the study appeared to be free of other sources of bias. Analyses were performed using R (version 3.2.0) (19 ) and the metaanalyses package metaphor (version 1.9 -6) (20 ).
Results

INCLUDED STUDIES
In total, we identified 49 257 abstracts for vitamin D 2 /D 3 and 22 648 for activated vitamin D (Fig. 1) . We excluded 64 854 abstracts because the studies were not RCTs, leaving 5615 and 1436 records for screening, respectively. Of these, we excluded 6614 on the basis of screening titles and abstracts because no vitamin D/ activated vitamin D was given, no control was present, or the study was not relevant for the endpoint of the study. Therefore, 437 studies were considered for systematic review by inspecting full-text articles. Of these, we excluded an additional 382 studies, including 299 that did not measure 1,25(OH) 2 D and 42 studies that did not provide all relevant 1,25(OH) 2 D data or had no groupspecific data. In 9 studies, the control group also received vitamin D, and in an additional 11 studies no control group was present. Twenty-one studies were excluded for other reasons (duplicate publication, common baseline characteristics for both cohorts, controls received phototherapy, no oral dosing, use of different dosages for different age groups, infants, patients received vitamin D 3 plus calcitriol). Thus, we included 55 studies in our systematic review ( Table 1 in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol61/ issue12). Our search did not identify articles of interest for our review in languages other than English.
The characteristics of the studies are shown in Table 1 
SYNTHESIS OF RESULTS OF VITAMIN D SUPPLEMENTATION
Substitution with vitamin D increases circulating 1,25(OH) 2 D by a mean of 12.2 pmol/L (95% CI, 7.8 -16.5; P Ͻ 0.001) (Fig. 2) . There was evidence for a significant heterogeneity among studies (Cochran Q ϭ 374.1; P Ͻ 0.001; I 2 ϭ 91%), confirming the need for a random effect model. To investigate heterogeneity, we evaluated in subgroup analyses the effect of age, vitamin D type, calcium coadministration, frequency of vitamin D intake, duration of vitamin D intake, baseline 25OHD concentration, vitamin D dose, methods of measurement, and CKD (Fig. 3A) . Compared with vitamin D supplements alone, concomitant calcium supplementation was associated with significantly lower increase in 1,25(OH) 2 Fig. 1) . Moreover, neither the Egger test for funnel asymmetries nor the nonparametric Begg-Mazumdar test was significant (P ϭ 0.13 and P ϭ 0.12, respectively).
Eighteen studies, published between 1995 and 2013, were considered to be of low risk of bias (see online Supplemental Fig. 2 ). In these studies (38.8% with calcium coadministration), the mean 1,25(OH) 2 a Patients with HIV, CKD, idiopathic hypercalciuria, galactosemia, heart failure, stroke, renal transplant, critical illness, osteoporosis, Parkinson disease, hypertension, impaired glucose tolerance, Paget disease, mixed. b For intervention groups. c Weekly supplementation for 8 weeks followed by monthly supplementation for 4 months in 1 study and 1 larger bolus dose followed by monthly supplementation for 5 months in the other study. A funnel plot of included studies on activated vitamin D is presented in online Supplemental Fig. 4 . A large treatment effect in one trial with the lowest precision could be indicative of publication bias. Indeed, the Egger test for funnel asymmetries was borderline significant (P ϭ 0.08), but the nonparametric Begg-Mazumdar test was not (P ϭ 0.16). None of the included studies provided sufficient information on criteria for judging study quality.
In 8 out of the 14 studies, in-study 25OHD concentrations were also provided. Administration of activated vitamin D did not significantly change circulating 25OHD concentrations (mean: 2.1 nmol/L; 95% CI, Ϫ2.8 to 7.0; P ϭ 0.35). No in-study 25OHD values were presented in the studies dealing with CKD patients. Vertical marks represent changes in circulating 1,25(OH) 2 D, and horizontal bars represent 95% CIs; a statistically significant result was assumed when the 95% CI did not include 0 (vertical line). a The numbers indicate the intervention group numbers listed in online Supplemental Table 1 for intervention groups with vitamin D.
Discussion
The present metaanalysis has several major findings. Ϫ/Ϫ mice) results in growth retardation, osteoporosis, kyphosis, skin thickening and wrinkling, ectopic calcification, progressive loss of hearing, and short lifespan (22 ) . Notably, in immunosuppressed solid-organ transplanted animals 1,25(OH) 2 D administration improved survival significantly (23, 24 ) . In line with these experimental data, the aforementioned clinical studies (8 -10 ) There is an ongoing debate about the effect of calcium supplements on clinical outcome: Several large cohort studies and metaanalyses of RCTs have provided evidence that calcium supplements may increase total mortality (31, 32 ) and other major clinical endpoints, such as myocardial infarction (33, 34 (38 -40 ) . These developments may substantially increase the numbers of studies measuring circulating 1,25(OH) 2 In conclusion, both vitamin D and activated vitamin D increase circulating 1,25(OH) 2 D concentrations substantially. In vitamin D users, but not in patients receiving activated vitamin D, this effect seems to be attenuated by calcium coadministration.
